OrbiMed’s McKesson MCK Stock Holding History

OrbiMed’s Portfolio MCK Stock Details MCK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-50,000	Closed	-$6.63M	–	144
2018 Q3	$6.63M	Buy	+50,000	New	+$6.52M	0.08%	123

Other funds holding MCK

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

VVP

Vulcan Value Partners Birmingham, Alabama $3.77B AUM 9.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

OrbiMed's MCK Position: Q4 2018 in Review

OrbiMed sold out of McKesson (MCK) in Q4 2018, closing a stake of 74,100 shares — an estimated $9.83M sold.

OrbiMed first reported a position in MCK in Q2 2013 and held it in 14 quarters. The position peaked at $161M in Q2 2015. 855 funds tracked by Wall St. Rank hold MCK as of Q4 2018.

OrbiMed reported no remaining McKesson position as of Q4 2018 after selling out during the quarter.
OrbiMed sold 74,100 McKesson shares in Q4 2018, an estimated $9.83M.
OrbiMed first reported a position in McKesson in Q2 2013 and held it in 14 quarters.
OrbiMed's McKesson position peaked at $161M in Q2 2015.
855 funds tracked by Wall St. Rank held McKesson as of Q4 2018.

Based on OrbiMed's 13F filing for Q4 2018, filed 14 Feb 2019.